IRIDEX Corporation — Q3 2017 Form 10-Q
Reporting period: Quarter ended September 30, 2017; comparative quarter ended October 1, 2016. The company develops and sells ophthalmic medical lasers, delivery devices, consumables, and related services. Amounts below are in millions of dollars unless stated otherwise.
Financial results and liquidity
| Metric | Q3 2017 | Q3 2016 | Nine months 2017 | Nine months 2016 |
|---|---|---|---|---|
| Revenue | $10.87 | $9.79 | $31.35 | $33.63 |
| Gross profit / margin | $4.37 / 40.2% | $4.25 / 43.4% | $13.33 / 42.5% | $15.28 / 45.4% |
| Operating loss | $(3.07) | $(1.25) | $(7.67) | $(1.49) |
| Net loss | $(3.10) | $(0.67) | $(7.71) | $(0.90) |
| Basic and diluted loss per share | $(0.27) | $(0.07) | $(0.67) | $(0.09) |
- Cash and cash equivalents were $22.75 million at September 30, 2017, versus $23.75 million at December 31, 2016; working capital was $33.8 million, down from $37.4 million.
- For the first nine months, operating cash use was $2.63 million, investing cash use was $0.66 million, and financing provided $2.30 million. Cash declined by $1.00 million.
- The company had no interest-bearing debt outstanding. Total liabilities were $8.51 million, including $6.09 million of operating lease commitments and $7.43 million of purchase commitments.
- Current assets were $41.48 million and current liabilities were $7.71 million. The filing reports no material off-balance-sheet arrangements.
Changes and management commentary
- Q3 revenue grew 11.0%, led by international system sales (+40.2%) and domestic system sales (+12.1%). Recurring revenue declined 0.9% as lower legacy probe sales mostly offset growth in G6-related probes.
- Nine-month revenue fell 6.8%. Domestic and international system sales declined 12.8% and 12.1%, respectively; recurring revenue fell 1.0%. System sales weakness was concentrated in surgical retina and glaucoma, partly offset by medical retina growth.
- Gross margin declined in both periods. Management attributed Q3 pressure mainly to product and geographic mix and manufacturing variances; for the nine-month period, lower overhead absorption, manufacturing variances, and higher overhead spending were key factors.
- Operating expenses rose substantially: Q3 sales and marketing increased 58.5% and general and administrative expenses 30.4%; nine-month increases were 43.5% and 15.0%, respectively. Management cited increased headcount and related costs, commissions, recruiting, severance, and public-company compliance costs.
- Financing cash included $2.26 million of net proceeds from a common-stock issuance and $0.33 million from option exercises. Shares outstanding were 11,579,379 at October 19, 2017.
Outlook, risks, and unusual items
- Management stated that existing cash and cash equivalents should be sufficient for anticipated cash needs over the next 12 months. The filing gives no specific revenue, earnings, or margin guidance.
- Key risks include product quality and manufacturing execution, reliance on sole- or limited-source suppliers and international distributors, competitive pressure, reimbursement and regulatory changes, product adoption, and the ability to scale a growing sales organization. Management noted that expanding sales staff can increase costs before new representatives become productive.
- In March 2017, IRIDEX began offering a five-year warranty on laser heads for IQ 532/577 consoles, compared with its prior one-to-two-year product warranties. Warranty liability totaled $0.68 million at September 30, 2017.
- In August 2017, the company sold certain intellectual property for $0.175 million, recorded as a gain. The RetinaLabs earn-out liability was $0.52 million, down from $0.69 million at year-end, reflecting payments and fair-value changes.
- The company recorded a full valuation allowance on federal and state deferred tax assets in Q4 2016; it reported a $0.023 million tax provision for the first nine months of 2017. Management said no subsequent events requiring disclosure occurred.
- Disclosure controls and procedures were deemed effective at the reasonable-assurance level as of September 30, 2017; no material change in internal control over financial reporting was reported. Ordinary-course legal matters were not expected by management to have a material adverse effect.
Important facts for investors to verify
- Whether Q3 system-sales growth can be sustained, particularly given the nine-month decline in system revenue and weakness in surgical retina and glaucoma.
- Whether gross margins recover from lower levels and manufacturing variances, and whether higher sales and marketing spending produces commensurate revenue growth.
- Cash-burn trends and the assumptions behind management’s estimate that cash will cover anticipated needs for the next 12 months.
- The effects of the longer IQ 532/577 laser-head warranty on future warranty costs, and the sensitivity of the RetinaLabs earn-out estimate to projected royalties and discount rates.
- Potential dilution and future capital needs, including the impact of stock-based awards and the 2017 common-stock issuance.